Natixis Investment Managers International Buys Shares of 1,175 Cencora, Inc. (NYSE:COR)

Natixis Investment Managers International purchased a new position in Cencora, Inc. (NYSE:COR) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,175 shares of the company’s stock, valued at approximately $286,000.

Several other institutional investors also recently modified their holdings of COR. Rise Advisors LLC purchased a new stake in shares of Cencora during the first quarter valued at $25,000. Legacy Bridge LLC purchased a new stake in shares of Cencora during the first quarter valued at $27,000. TCTC Holdings LLC purchased a new stake in shares of Cencora during the first quarter valued at $29,000. WASHINGTON TRUST Co purchased a new stake in shares of Cencora during the first quarter valued at $32,000. Finally, Hanson & Doremus Investment Management bought a new position in Cencora in the first quarter valued at about $33,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the stock in a transaction that occurred on Wednesday, May 22nd. The shares were sold at an average price of $215.12, for a total transaction of $399,991,976.80. Following the transaction, the insider now directly owns 24,418,171 shares in the company, valued at $5,252,836,945.52. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the company’s stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $215.12, for a total transaction of $399,991,976.80. Following the completion of the sale, the insider now directly owns 24,418,171 shares in the company, valued at approximately $5,252,836,945.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Dermot Mark Durcan bought 500 shares of the business’s stock in a transaction on Friday, May 24th. The stock was bought at an average price of $218.58 per share, for a total transaction of $109,290.00. Following the purchase, the director now directly owns 21,876 shares of the company’s stock, valued at $4,781,656.08. The disclosure for this purchase can be found here. Insiders have sold a total of 1,899,112 shares of company stock worth $408,654,376 in the last three months. Corporate insiders own 15.80% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on COR shares. Citigroup raised their price objective on Cencora from $265.00 to $280.00 and gave the stock a “buy” rating in a research note on Tuesday, April 30th. Robert W. Baird upped their price target on shares of Cencora from $280.00 to $285.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 9th. SVB Leerink restated an “outperform” rating and set a $275.00 price objective on shares of Cencora in a research report on Thursday, June 27th. Finally, StockNews.com cut shares of Cencora from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 2nd. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $238.78.

Cencora Trading Up 0.5 %

Shares of COR traded up $1.13 during midday trading on Thursday, hitting $227.11. The stock had a trading volume of 969,411 shares, compared to its average volume of 1,363,092. Cencora, Inc. has a 1 year low of $171.65 and a 1 year high of $246.75. The company has a debt-to-equity ratio of 3.41, a current ratio of 0.89 and a quick ratio of 0.53. The stock’s 50 day moving average is $226.75 and its 200 day moving average is $230.39. The firm has a market cap of $45.30 billion, a PE ratio of 24.89, a price-to-earnings-growth ratio of 1.56 and a beta of 0.45.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, May 1st. The company reported $3.80 EPS for the quarter, topping analysts’ consensus estimates of $3.65 by $0.15. Cencora had a net margin of 0.67% and a return on equity of 268.67%. The firm had revenue of $68.41 billion for the quarter, compared to analysts’ expectations of $70.60 billion. During the same period in the prior year, the business posted $3.50 earnings per share. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. As a group, analysts forecast that Cencora, Inc. will post 13.46 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, May 24th. Investors of record on Friday, May 10th were paid a $0.51 dividend. This represents a $2.04 dividend on an annualized basis and a yield of 0.90%. The ex-dividend date was Thursday, May 9th. Cencora’s dividend payout ratio (DPR) is presently 22.32%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.